Combined treatment with lenalidomide and epoetin alfa leads to durable responses in patients with epo-refractory, lower risk non-deletion 5q [del(5q)] MDS: Final results of the E2905 intergroup phase III study - An ECOG-ACRIN Cancer Research Group study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health Meeting Abstract
| Authors: | List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K.; Maciejewski, J. P.; Komrokji, R. S.; Wassenaar, T. R.; Luger, S. M.; Mattison, R. J.; Cheema, P. S.; Altman, J. K.; Claxton, D. F.; Schiffer, C. A.; Artz, A. S.; Litzow, M.; Tallman, M. S. |
| Abstract Title: | Combined treatment with lenalidomide and epoetin alfa leads to durable responses in patients with epo-refractory, lower risk non-deletion 5q [del(5q)] MDS: Final results of the E2905 intergroup phase III study - An ECOG-ACRIN Cancer Research Group study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | 13 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000518218500696 |
| DOI: | 10.1182/blood-2019-127274 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 842 -- Source: Wos |
